IRLAB-A.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:29):

Stats
今日成交量	53 070.00
平均成交量	87 549.00
市值	530.83M
EPS	SEK0 ( 2024-02-06 )
下一个收益日期	( SEK0 ) 2024-05-08
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-3.02
ATR14	SEK0.106 (1.03%)

音量相关性

長: -0.29 (neutral)

短: 0.13 (neutral)

Signal:(42.465) Neutral

IRLAB Therapeutics AB 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

IRLAB Therapeutics AB 相关性 - 货币/商品

0.42
( neutral )

0.00
( neutral )

0.28
( neutral )

-0.22
( neutral )

-0.51
( weak negative )

IRLAB Therapeutics AB 财务报表

Annual	2023
营收:	SEK5.68M
毛利润:	SEK-180.13M (-3 172.46 %)
EPS:	SEK-3.43

FY	2023
营收:	SEK5.68M
毛利润:	SEK-180.13M (-3 172.46 %)
EPS:	SEK-3.43

FY	2022
营收:	SEK61.14M
毛利润:	SEK-111.23M (-181.94 %)
EPS:	SEK-2.20

FY	2021
营收:	SEK207.78M
毛利润:	SEK0.00 (0.00 %)
EPS:	SEK0.494

Financial Reports:

No articles found.

IRLAB Therapeutics AB

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.